According to Zacks, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. “
Several other research analysts also recently weighed in on the company. Mizuho lifted their target price on Eagle Pharmaceuticals from $47.00 to $65.00 and gave the company a neutral rating in a research note on Tuesday, August 16th. TheStreet upgraded Eagle Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, August 9th. Finally, Royal Bank Of Canada reiterated a buy rating and issued a $78.00 target price on shares of Eagle Pharmaceuticals in a research note on Monday, June 13th. Three equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Eagle Pharmaceuticals currently has an average rating of Buy and a consensus price target of $90.24.
Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) opened at 66.28 on Tuesday. The firm has a 50-day moving average price of $60.43 and a 200 day moving average price of $47.88. The stock has a market capitalization of $1.04 billion, a PE ratio of 339.90 and a beta of 1.18. Eagle Pharmaceuticals has a one year low of $33.02 and a one year high of $102.48.
Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.09. Eagle Pharmaceuticals had a return on equity of 3.44% and a net margin of 3.45%. The company had revenue of $40.90 million for the quarter, compared to the consensus estimate of $43.55 million. During the same period last year, the business posted ($0.53) EPS. The company’s revenue was up 581.7% on a year-over-year basis. On average, equities analysts expect that Eagle Pharmaceuticals will post $3.21 EPS for the current fiscal year.
In related news, major shareholder Proquest Investments Iv, L.P. sold 24,949 shares of Eagle Pharmaceuticals stock in a transaction on Monday, August 15th. The stock was sold at an average price of $60.77, for a total transaction of $1,516,150.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 18.80% of the company’s stock.
A number of institutional investors have recently modified their holdings of EGRX. BlackRock Group LTD boosted its position in shares of Eagle Pharmaceuticals by 62.9% in the first quarter. BlackRock Group LTD now owns 2,916 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 1,126 shares in the last quarter. White Pine Capital LLC bought a new position in Eagle Pharmaceuticals during the second quarter worth $208,000. LaSalle Street Capital Management LLC bought a new position in Eagle Pharmaceuticals during the second quarter worth $304,000. Columbus Circle Investors bought a new position in Eagle Pharmaceuticals during the second quarter worth $306,000. Finally, Rhumbline Advisers boosted its position in Eagle Pharmaceuticals by 3.3% in the second quarter. Rhumbline Advisers now owns 9,295 shares of the specialty pharmaceutical company’s stock worth $361,000 after buying an additional 297 shares during the period. 95.67% of the stock is owned by hedge funds and other institutional investors.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.